Full-Time

Director – Finance Business Partner

Finance, Commercial Operations

Posted on 9/17/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA

In Person

Category
Finance & Banking (2)
,
Required Skills
Power BI
QlikView
Tableau
Data Analysis
Excel/Numbers/Sheets
Financial Modeling
Requirements
  • 10+ years of progressive experience in business planning, commercial analysis, or business partnering roles, preferably in the pharmaceutical or biotech industry.
  • 5+ years in commercial finance in a business facing role where there is demonstrated understanding of the value chain in US life sciences, preferably in rare disease.
  • Advanced skills in Excel and experience with ERP and BI systems (e.g., SAP S/4, BW/BI, BPC, SAC, Power BI, QlikView, Tableau). Familiarity with Model N is a plus.
Responsibilities
  • Be the principal financial partner to executives in the US region.
  • Shape commercial and marketing strategies with financial guidance to ensure resource allocation, profitability, and Return on investment.
  • Support brand planning, new product launches, and go-to-market strategies through forecasting, financial modeling, and performance tracking.
  • Create analytics and strategic insight for sales performance, pricing, and contracting across payer segments (including Medicaid, Medicare, and Commercial).
  • Collaborate with (Contracting, Market Access, Government Pricing, Patient Services) to evaluate Gross-to-Net components and improve contra revenue elements (e.g., rebates, chargebacks, admin fees).
  • Lead revenue forecasting, net sales analysis, and expense planning within Integrated Business Planning (IBP) and Demand Review Management (DRM) cycles.
  • Build scenario models to assess performance risk, growth opportunities, and resource trade-offs.
  • Develop and track indicators for Sales, Volume, GTN, Marketing Spend Effectiveness, and Margin.
  • Influence decision-making across the Commercial Operations responsibility by providing clear financial insights.
  • Lead the consolidation and financial oversight of operational expenses across areas translating functional plans into a cohesive financial outlook, delivering executive-level performance narratives that highlight important causes, risks and opportunities, and applying insights to support prioritization of resources and optimization of investments.
  • Support delivery of the Finance Strategy and have collective ownership for Global Finance team development plans. Manage without formal authority in matrix environment.
  • Provide external financial audit support at half-year and full year, including preparation of documentation and manage and, working with auditors to provide business insight for items as requested and resolution of issues raised following agreed timelines.
  • Support ensuring that financial processes follow CSL policies and that proper controls are in place, as applicable.
  • Support and mentor a team, providing guidance and professional development opportunities. Foster a collaborative environment that inspires results.
  • Contribute to projects, global finance plans, transformation projects and process optimization efforts as assigned.
Desired Qualifications
  • Openness to explore new technology, process improvements.
  • You will collaborate with multiple levels and within a region.

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE